Richard A. Van Etten, MD, PhD, Director of the NCI-designated Chao Family Comprehensive Cancer Center at the University of California, Irvine, speaks about the late-breaking positive performance data of HelioLiver™ for early liver cancer detection.
Helio Health and its commercial partner, Fulgent Genetics, Inc., presented fresh data at AASLD proving the effectiveness of HelioLiver in detecting hepatocellular carcinoma in its early stages (HCC). HelioLiver’s sensitivity was 76 percent in early-stage HCC and 85 percent in overall HCC, exhibiting greater performance over alpha-fetoprotein (AFP) alone and the GALAD model, with 91 percent specificity.
HelioLiver is a multi-analyte blood test that detects early-stage HCC with high accuracy using both cell-free DNA (cfDNA) methylation patterns and protein tumor markers. HelioLiver has the potential to improve morbidity and mortality in people with HCC since there are more curative therapy choices when the malignancy is detected early. A highly sensitive blood test can encourage patients to follow surveillance guidelines and make HCC detection more convenient and cost-effective.
The ENCORE study used blood samples from 303 people in a blinded, multicenter validation study. There were 122 people identified with HCC, 125 people diagnosed with benign liver disease, and 56 people diagnosed with other cancers in the study.
Beginning November 8, 2021, guests of The Liver Meeting® were able to see a poster presentation titled “A Multi-Analyte Blood Test for Accurate and Early Detection of Hepatocellular Carcinoma.”
In Helio’s pivotal prospective trial, CLiMB, the HelioLiver test was still being reviewed (NCT: 03694600).
Watch the interview on OncologyTube →
View source version on prnewswire.com.